Andromeda Capital’s Biogen BIIB Stock Holding History

Andromeda Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-25,400	Closed	-$8.4M	–	54
2014 Q3	$8.4M	Buy	+25,400	New	+$8.37M	0.5%	51

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Andromeda Capital's BIIB Position: Q4 2014 in Review

Andromeda Capital sold out of Biogen (BIIB) in Q4 2014, closing a stake of 11,702 shares — an estimated $3.87M sold.

Andromeda Capital first reported a position in BIIB in Q3 2014 and held it in 1 quarter. The position peaked at $3.87M in Q3 2014. 884 funds tracked by Wall St. Rank hold BIIB as of Q4 2014.

Andromeda Capital reported no remaining Biogen position as of Q4 2014 after selling out during the quarter.
Andromeda Capital sold 11,702 Biogen shares in Q4 2014, an estimated $3.87M.
Andromeda Capital first reported a position in Biogen in Q3 2014 and held it in 1 quarter.
Andromeda Capital's Biogen position peaked at $3.87M in Q3 2014.
884 funds tracked by Wall St. Rank held Biogen as of Q4 2014.

Based on Andromeda Capital's 13F filing for Q4 2014, filed 17 Feb 2015.